Journal of Plastic, Reconstructive & Aesthetic Surgery
Volume 64, Issue 4 , Pages 445-451 , April 2011

Propranolol as first-line treatment for rapidly proliferating Infantile Haemangiomas

Received 8 June 2010 ,Accepted 16 July 2010.

References 

  1. Enjolras O, Gelbert F. Superficial hemangiomas: associations and management. Pediatr Dermatol. 1997 May–Jun;14:173–179
  2. Enjolras O, Mulliken JB. Vascular tumors and vascular malformations. Adv Dermatol. 1997;13:375–423(new issues)
  3. Baetz J, Eigelshoven S, Marquard J, et al. Infantile hemangioma. Successful treatment with propranolol, Hautarzt. 2010 Apr;61:290–292
  4. Zimmerman AP, Wiegand S, Werner JA, et al. Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolaryngol. 2010;74(4):338–342
  5. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy, N Eng J Med. 2008;358(24):2649–2651
  6. Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7–9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol. 2005 Sep–Oct;22:383–406
  7. Haggstrom AN, Lammer EJ, Schneider RA, et al. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics. 2006;117(3):698–703
  8. Enjolras O. Classification and management of the various superficial vascular anomalies: hemangiomas and vascular malformations. J Dermatol. 1997 Nov;24:701–710
  9. Metz BJ, Rubenstein MC, Levy ML, et al. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol. 2004 Jul;140:867–870
  10. Frieden IJ, Eichenfield LF, Esterly NB, et al. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol. 1997 Oct;37:631–637
  11. Bennett ML, Fleischer AB, Chamlin SL, et al. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001 Sep;137:1208–1213
  12. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999;104(6):1616–1623
  13. George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004;140(8):963–969
  14. Lomenick JP, Reifschneider KL, Lucky AW, et al. Prevalence of adrenal insufficiency following systemic glucocorticoid therapy in infants with hemangiomas. Arch Dermatol. 2009 Mar;145:262–266
  15. Constantinides Y, Gorst C, Didi M, Liew S. Adrenal suppression after steroid treatment of infantile hemangioma. Poster presentation at the 18th International Workshop on Vascular Anomalies. [Poster]. 2010.
  16. Denoyelle F, Leboulanger N, Enjolras O, et al. Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol. 2009;1168–1172
  17. Buckmiller L. Propranolol treatment for infantile hemangiomas, Current opinion in otolaryngology & head and neck surgery. 2009 Oct 23;
  18. Holmes WJM, Mishra A, Gorst C, et al. Propranolol as first-line treatment for infantile hemangiomas. Plastic and Reconstructive Surgery. 2010 Jan 1;125(1):420–421
  19. Jephson C, Manunza F, Syed S, et al. Successful treatment of isolated subglottic haemangioma with propranolol alone, Int J Pediatr Otorhinolaryngol. 2009 Sep 29;
  20. Sans V, De La Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009 Sep 1;124(3):e423–e431
  21. Michel JL, Patural H. Response to oral propranolol therapy for ulcerated hemangiomas in infancy. Arch Pediatr. 2009 Dec;16(12):1565–1568
  22. Theletsane T, Redfern A, Raynham O, et al. Life-threatening infantile haemangioma: a dramatic response to propranolol. J Eur Acad Dermatol Venereol. 2009 Dec 1;23(12):1465–1466
  23. Marsciani A, Pericoli R, Alaggio R, et al. Massive response of severe infantile hepatic hemangioma to propanolol. Pediatr Blood Cancer. 2010 Jan 1;54(1):176
  24. Fay A, Nguyen J, Jakobiec FA, et al. Propranolol for isolated orbital infantile hemangioma. Arch Ophthalmol. 2010 Feb 1;128(2):256–258
  25. Qin ZP, Liu XJ, Li KL, et al. Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety, Zhonghua Yi Xue Za Zhi. 2009 Dec 1;89:3130–3134
  26. O T, Waner M, Xu D, Shatava A, Blei F, Ward D, et al. Vandetanib and prorpanolol inhibit Infantile Hemangioma (IH) and NICH Cell growth in vitro. Oral presentation at the 18th International Workshop on Vascular Anomalies. [Oral Presentation]. 2010.
  27. Yang Q, Kumar S, Salalto V, Szabo S, North PE. Prorpanolol inhibits proliferation and tube formation by purified placental capillary endothelial cells, an in vitro model for infantile hemangioma (IH), and induces their apoptosis. Oral presentation at the 18th International Workshop on Vascular Anomalies. [Oral Presentation]. 2010 23/04/2010.
  28. Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol. 2003 Apr;48:477–493quiz 94–6
  29. Bigorre M, Van Kien AK, Valette H. Beta-blocking agent for treatment of infantile hemangioma. Plast Reconstr Surg. 2009 Jun;123:195e–196e
  30. Shashidhar H, Langhans N, Grand RJ. Propranolol in prevention of portal hypertensive hemorrhage in children: a pilot study. J Pediatr Gastroenterol Nutr. 1999 Jul;29:12–17
  31. Zacharias FJ. Patient acceptability of propranolol and the occurence of side effects. Postgrad Med J. 1976;52:87–89
  32. Artman M, Grayson M, Boerth RC. Propranolol in children: safety-toxicity. Pediatrics. 1982 Jul;70:30–31
  33. Love JN, Sikka N. Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers. J Emerg Med. 2004 Apr 1;26(3):309–314
  34. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009 Jan 1;26(5):610–614
  35. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas - insights into the molecular mechanisms of action. Br J Dermatol. 2010 May 8;
  36. Iaccarino G, Ciccarelli M, Sorriento D, et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res. 2005 Nov 25;97(11):1182–1189
  37. Takahashi K, Mulliken JB, Kozakewich HP, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest. 1994 Jun 1;93(6):2357–2364
  38. Tan ST, Velickovic M, Ruger BM, et al. Cellular and extracellular markers of hemangioma. Plast Reconstr Surg. 2000 Sep 1;106(3):529–538
  39. Hattori Y, Yamamoto S, Matsuda N. Sympathetic control of VEGF angiogenic signaling: dual regulations by alpha 2-adrenoceptor activation?. Circ Res. 2007 Sep 28;101(7):642–644
  40. Fredriksson JM, Lindquist JM, Bronnikov GE, et al. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta -adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2. J Biol Chem. 2000 May 5;275(18):13802–13811
  41. Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004 Nov 1;64:7822–7835
  42. Pritchard-Jones RO, Dunn DB, Qiu Y, et al. Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer. 2007 Jul 16;97:223–230

☆ This data has been presented at:1. BAPRAS December 2009, Royal College of Surgeons, UK.2. 10th ISSVA–18th International Workshop on Vascular Anomalies Conference April 2010, Belgium.

PII: S1748-6815(10)00419-5

doi: 10.1016/j.bjps.2010.07.009

Journal of Plastic, Reconstructive & Aesthetic Surgery
Volume 64, Issue 4 , Pages 445-451 , April 2011

Article Tools

* Image Usage & Resolution